Loading...
FibroGen Community
NasdaqGS:FGEN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
Community Investing Ideas
Clinical Trials And Regulatory Advances Will Open US Markets
Key Takeaways Advancing precision oncology and rare disease treatments positions the company for future revenue growth and strong market opportunities in underserved populations. Liquidity improvements and strategic pipeline diversification reduce financial risk while enhancing long-term earnings stability and optionality.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$43
74.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-3.88% p.a.
Profit Margin
16.06%
Future PE
216.47x
Share price in 2028
US$55.54